Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
Christopher D. Maggiore, a director and significant shareholder of Zivo Bioscience, Inc. (NASDAQ:ZIVO), recently executed a sale of company shares. According to the latest SEC filing, Maggiore sold 20 shares of common stock on April 8, 2025, at a price of $16.25 per share, totaling $325. Following this transaction, Maggiore holds 507,000 shares in the company, representing a significant stake in this $60 million market cap biotechnology firm. The stock, which has declined nearly 20% over the past six months, currently trades near InvestingPro's Fair Value estimate. InvestingPro analysis reveals the stock typically moves opposite to broader market trends, making it an interesting diversification option. Subscribers can access 8 additional key insights about ZIVO on InvestingPro.
In other recent news, Zivo Bioscience has reported the issuance of new equity shares, raising approximately $1.5 million. According to a recent 8-K filing with the Securities and Exchange Commission, the company sold 75,000 shares to one accredited investor at a price of $20.19 per share. Additionally, Zivo Bioscience has granted 38,478 shares as restricted stock to non-employee members of its board of directors under its 2024 Equity Incentive Plan. In a related development, the company announced an Exchange Program, issuing 78,320 shares to certain investors in exchange for the cancellation of specific agreements and associated revenue-sharing arrangements. These transactions were conducted privately, without public offerings or general solicitation, and were not registered under the Securities Act of 1933. Instead, they were offered to accredited investors under specific exemptions. As of January 22, 2025, Zivo Bioscience has a total of 3,738,033 shares of common stock outstanding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.